노보 노디스크(NVO) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

NVO

Novo Nordisk ADR

7월 24일 4:00 PM ET (한국 7/25 05:00)

$48.77

+0.59 ▲ +1.22%

🌙 7월 27일 8:35 AM ET (한국 7/27 21:35)

$49.32

+0.55 ▲ +1.13%

노보 노디스크(NVO) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$163.8B

미드캡

P/E

11.4

저평가 구간

배당수익률

3.66%

52주 위치

37%

저점 +39% · 고점 -32%

애널리스트

매수

C+

Fundamental health

vs. Drug Manufacturers - General

수익성

Top 2%

성장

Top 40%

밸류에이션

Top 56%

재무 안정

Top 87%

Index ⓘ	-	P/E ⓘ	11.45	EPS (ttm) ⓘ	4.26	Insider Own ⓘ	-	Shs Outstand ⓘ	3.37B	Perf Week ⓘ	-3.08%
Market Cap ⓘ	163.77B	Forward P/E ⓘ	14.88	EPS next Y ⓘ	0.09%	Insider Trans ⓘ	-	Shs Float ⓘ	3.36B	Perf Month ⓘ	2.87%
Enterprise Value ⓘ	183.01B	PEG ⓘ	-	EPS next Q ⓘ	0.77	Inst Own ⓘ	9.81%	Short Float ⓘ	0.83%	Perf Quarter ⓘ	26.61%
Income ⓘ	18.95B	P/S ⓘ	3.22	EPS this Y ⓘ	-9.98%	Inst Trans ⓘ	-2.77%	Short Ratio ⓘ	2.07	Perf Half Y ⓘ	-21.63%
Sales ⓘ	50.91B	P/B ⓘ	6.92	EPS next 5Y ⓘ	-0.89%	ROA ⓘ	24.14%	Short Interest ⓘ	27.78M	Perf YTD ⓘ	-4.15%
Book/sh ⓘ	7.05	P/C ⓘ	49.11	EPS past 3/5Y ⓘ	26.28% 20.36%	ROE ⓘ	73.79%	52W High ⓘ	-32.07% ($71.79)	Perf Year ⓘ	-31.05%
Cash/sh ⓘ	0.99	P/FCF ⓘ	25.53	Sales past 3/5Y ⓘ	23.19% 19.21%	ROIC ⓘ	38.15%	52W Low ⓘ	38.87% ($35.12)	Perf 3Y ⓘ	-39.82%
Dividend Est. ⓘ	$1.79 (3.66%)	EV/EBITDA ⓘ	6.9	EPS Y/Y TTM ⓘ	26.24%	Gross Margin ⓘ	81.84%	Volatility(W/M) ⓘ	2.29% 2.13%	Perf 5Y ⓘ	7.48%
Dividend TTM ⓘ	1.8	EV/Sales ⓘ	3.59	Sales Y/Y TTM ⓘ	16.79%	Oper. Margin ⓘ	45.45%	ATR (14) ⓘ	1.26	Perf 10Y ⓘ	75.34%
Dividend Ex-Date ⓘ	2026/3/30	Quick Ratio ⓘ	0.56	EPS Q/Q ⓘ	86.54%	Profit Margin ⓘ	37.23%	RSI (14) ⓘ	53.46	Recom ⓘ	2.35
Dividend Gr. 3/5Y ⓘ	26.98% 19.93%	Current Ratio ⓘ	0.79	Sales Q/Q ⓘ	37.63%	SMA20 ⓘ	-0.93% ($49.23)	Beta ⓘ	0.77	Target Price ⓘ	$49.8
Payout ⓘ	36.87%	Debt/Eq ⓘ	0.72	Earnings ⓘ	2026/5/6	SMA50 ⓘ	5.24% ($46.34)	Rel Volume ⓘ	0.8	Prev Close ⓘ	$48.18
Employees ⓘ	68794	LT Debt/Eq ⓘ	0.59	EPS/Sales Surpr. ⓘ	18.04% 1.5%	SMA200 ⓘ	3.44% ($47.15)	Avg Volume(3M) ⓘ	13.42M	Price ⓘ	$48.77
IPO ⓘ	1981/4/30	Option/Short ⓘ	Yes/Yes			Trades ⓘ	41620	Volume ⓘ	10,771,140	Change ⓘ	1.22%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Novo Nordisk ADR (NVO) Investment Analysis

What kind of company is Novo Nordisk ADR?

노보 노디스크(NVO) 배당주

Healthcare · Drug Manufacturers - General

Top 98 by Market Cap — Global Large-Cap

A global leader in the diabetes and obesity treatment market, this pharmaceutical company was founded in Denmark in 1923 and is headquartered near Copenhagen. It holds a top global market share in insulin products and GLP-1-based obesity and diabetes treatments, with a core brand portfolio that includes Wegovy, Ozempic, and Rybelsus.

Learn more about Novo Nordisk ADR →

Market Cap

$164B

Approx. KRW 224 trillion

⚖️ 56% of Samsung Electronics

Market Cap Rank98

Employees68,794people

IPO1981/04/30

Current Price$48.77 ≈ 66,815원

NYSE · Denmark

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 6일 (수) · 장 시작 전 EPS +18.0% 매출 +1.5%

🎯 Ex-div 2026년 3월 30일 (월)

🔔 Earnings release 2026년 2월 4일 (수) · 장 시작 전 EPS +3.4% 매출 +3.1%

Is it profitable?

Profitable but financially weak

High debt load may weigh on results in a downturn

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

45.5%

✓ 우수

My positionTop 5%

Low range Average High range

Drug Manufacturers - General Median 27.0% · Top 2%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

37.2%

✓ 우수

My positionTop 5%

Low range Average High range

Drug Manufacturers - General Median 14.7% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

81.8%

✓ 우수

My positionTop 25%

Low range Average High range

Drug Manufacturers - General Median 69.3% · Top 8%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

73.8%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 11.9% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

24.1%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 5.1% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

38.1%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 7.4% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.72

✓ Healthy debt

My positionMid-range

Low range Average High range

Drug Manufacturers - General Median 0.94

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

0.79

✓ 매우 부진

My positionBottom 5%

Low range Average High range

Drug Manufacturers - General Median 1.26

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.56

✓ 매우 부진

My positionBottom 5%

Low range Average High range

Drug Manufacturers - General Median 1.01

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$49.80

현재가 대비 +2.1%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

14.88배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+0.1%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

-0.9%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

-0.7%

평균 서프라이즈

2026.05.06

하회

실적 $6.63 · 예상 $6.96 -4.8%

2026.02.04

상회

+3.4%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-10.0%

부진

My positionBottom 25%

Low range Average High range

배당주 대형주 Median 5.5% · Bottom 18%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+0.1%

부진

My positionBottom 25%

Low range Average High range

배당주 대형주 Median 7.3% · Bottom 20%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

-0.9%

부진

My positionBottom 25%

Low range Average High range

배당주 대형주 Median 6.7% · Bottom 14%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+26.3%

우수

My positionTop 25%

Low range Average High range

배당주 대형주 Median 4.1% · Top 12%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+20.4%

우수

My positionTop 25%

Low range Average High range

배당주 대형주 Median 6.3% · Top 19%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+19.2%

우수

My positionTop 5%

Low range Average High range

배당주 대형주 Median 6.7% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+37.6%

우수

My positionTop 5%

Low range Average High range

배당주 대형주 Median 5.9% · Top tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -60%p below the market

NVO +7.5% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-60.5%p

Significantly behind the market

vs Health Care (XLV)

-16.2%p

behind the sector average

1-year basis

vs S&P 500

-47.5%p

Significantly behind the market

vs Health Care (XLV)

-50.8%p

Significantly behind the sector average

Current position within 52-week range

Low (-38.9%p) High (-32.1%p)

Current price is 38.9% above the 52-week low and 32.1% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-29.8%

Annualized volatility

46.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-24

Downtrend zone

Current price $48.77 below the midline ($49.23). Normal downward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-24

Neutral zone — weak trend

MACD 0.827 · Signal 1.167 · Hist -0.340. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-24

Bullish zone

RSI 53.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 20.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Earnings, In line with peers on Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Mid-range

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

11.45x

✓ Very cheap

My positionTop 5%

Low range Average High range

Drug Manufacturers - General median 20.25x · Top 1% — relatively cheap within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

14.88x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - General median 13.52x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

6.92x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - General median 6.32x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

3.22x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - General median 3.17x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

6.90x

✓ Very cheap

My positionTop 5%

Low range Average High range

Drug Manufacturers - General median 11.04x · Top 1% — relatively cheap within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

25.53x

✓ Pricey

My positionBottom 25%

Low range Average High range

Drug Manufacturers - General median 15.70x · Bottom 15% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$49.80 vs. current price +2.1%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - General

Who owns it?

Ownership flow shows some pressure

Institutional net selling -2.8% · Short interest light 0.8%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

No trading data for Insiders

🏦 Institutions (funds & investors)

-2.8%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 9.8%

Retail-led

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 0.0%

Low, common among large-caps

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 90.2%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.8%

Low — limited short-side pressure

Healthcare 대형주 Median 3.6%

Past 89 days Little change

Short interest days to cover

2.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 3.37B주

Float (tradable shares) 3.36B주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

ETFs holding NVO

ETFs with the highest weightings · 10 total shown

NVOH

Novo Nordisk A/S (B Shares) ADRhedged

93.79%

$4M

EDEN

iShares MSCI Denmark ETF

17.15%

$200M

OZEM

Roundhill GLP-1 & Weight Loss ETF

13.13%

$62M

XRPI

Volatility Shares Trust XRP ETF

11.89%

$91M

NDIV

Amplify Energy & Natural Resources Covered Call ETF

11.89%

$27M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당주 — 연 3.66% 배당

5년 배당 성장률 19.93%

Dividend Yield

3.66%

Industry average 1.25%

Dividend Per Share

$1.79

Annualized

Payout Ratio

37%

Share of net income paid as dividends

5-Year Growth

19.9%

Annualized dividend growth

🏆 7년 연속 배당 증가

📅 지급월 3월 · 8월

📊 총 이력 1982~2026 (58건)

연도별 배당 총액 추이

주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.

$0.71 +85.7%

2016

$0.57 -19.4%

2017

$0.57 +0.0%

2018

$0.62 +8.9%

2019

$0.65 +5.4%

2020

$0.75 +15.4%

2021

$0.81 +7.6%

2022

$1.04 +28.0%

2023

$1.44 +39.2%

2024

$1.68 +16.6%

2025

$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소

최근 배당 이력 총 58건

아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.

배당락일

주당 금액

지급일

당시 수익률

2026-03-30

$1.27

—

8.38%

2025-08-18

$0.584

—

3.13%

2025-03-31

$1.10

—

2.32%

2024-08-16

$0.513

—

1.40%

2024-03-22

$0.930

—

1.53%

2023-08-18

$0.442

—

1.13%

2023-03-24

$0.595

—

1.84%

2022-08-12

$0.292

—

2.03%

2022-03-25

$0.518

—

2.39%

2021-08-16

$0.279

—

1.46%

2021-03-26

$0.474

—

3.33%

2020-08-14

$0.259

—

2.67%

2020-03-27

$0.394

—

2.18%

2019-08-16

$0.225

—

3.30%

2019-03-22

$0.395

—

3.80%

2018-08-17

$0.234

—

3.39%

2018-03-23

$0.335

—

3.73%

2017-08-17

$0.237

—

2.51%

2017-03-23

$0.332

—

3.35%

2016-08-11

$0.224

—

3.04%

2016-03-18

$0.482

—

3.16%

2015-03-19

$0.380

—

3.30%

2014-03-21

$0.415

—

3.34%

2013-03-21

$0.318

—

3.52%

2012-03-22

$0.250

—

3.05%

2011-03-24

$0.182

—

2.62%

2010-03-25

$0.141

—

1.80%

2009-03-19

$0.103

—

2.24%

2008-03-13

$0.088

—

1.29%

2007-03-08

$0.061

—

2.60%

2006-03-09

$0.048

—

3.09%

2005-03-10

$0.042

—

2.79%

2004-03-17

$0.037

—

2.76%

2003-03-26

$0.026

—

1.57%

2002-03-13

$0.018

—

1.80%

2001-03-21

$0.016

—

1.86%

2000-11-17

$0.009

—

1.16%

2000-03-24

$0.012

—

1.42%

1999-03-25

$0.008

—

1.63%

1998-03-27

$0.008

—

0.86%

1997-04-25

$0.006

—

0.98%

1996-05-01

$0.004

—

1.21%

1996-04-24

$0.004

—

0.55%

1995-04-24

$0.004

—

1.39%

1994-04-26

$0.003

—

1.05%

1994-04-22

$0.003

—

1.05%

1993-04-22

$0.003

—

1.27%

1992-04-28

$0.003

—

0.74%

1991-04-19

$0.003

—

1.76%

1990-04-23

$0.003

—

1.40%

1989-04-21

$0.002

—

2.32%

1988-04-21

$0.003

—

1.86%

1987-04-20

$0.002

—

2.05%

1986-04-21

$0.002

—

1.02%

1985-04-19

$0.001

—

0.97%

1984-04-13

$0.001

—

0.59%

1983-04-13

$0.001

—

0.64%

1982-04-23

$0.000

—

0.14%

* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.

💰 내가 100만원 투자한다면

연간 배당금 (세후) 3.1만원

5년 누적 (세후) 23.2만원

* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 19.93% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
NVO This Stock	$163.8B	11.4 ▲	6.9 ▼	73.79% ▲	3.66% ▲	+1.2%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

Derivative ETFs for NVO

Leveraged, inverse, and covered call ETFs based on the underlying asset

1 derivative ETFs based on NVO (Leverage 1)

These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.

ℹ️ What is a Derivative ETF?

These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.

⚠️ Caution: Long-Term Holding

Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.

📈 Leverage 1 ETFs that move 2-3x with NVO (high volatility)